U.S. Banks Report Strong Q4 Profits Amid Investment Banking Surge 
Insignia Financial Shares Hit 3-Year High Amid Bain and CC Capital Bidding War 
S&P 500 Surges Ahead of Trump Inauguration as Markets Rally 
Why the Middle East is being left behind by global climate finance plans 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Mexico's Undervalued Equity Market Offers Long-Term Investment Potential 
Gold Prices Rise as Markets Await Trump’s Policy Announcements 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Wall Street Rebounds as Investors Eye Tariff Uncertainty, Jobs Report 
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside 
KiwiSaver shakeup: private asset investment has risks that could outweigh the rewards 
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 
Add as a preferred source on Google
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
